Novel insights into extracellular vesicles: An update on biomolecules, immunomodulation and clinical strategies in skin melanoma

Abstract

Highlights:

Keywords

extracellular vesicles / melanoma / tumour microenvironment / biomarkers / therapeutic strategies

References

[1] Lee KJ, Kao Y-C, Jiang A, et al. Subclinical fields of BRAF V600E-mutant melanocytes populate human skin and are enriched around melanoma and naevi. Br J Dermatol. 2025; 194(2):ljaf412.

[2] Yuan F, Jing M, Chen X, et al. Effect of neoadjuvant therapy on survival outcomes in patients with melanoma: a systematic review and meta-analysis. eClinicalMedicine. 2025; 88:103504.

[3] Rather RA. Oncogenic B-Raf proto-oncogene, serine/threonine kinase-mediated hedgehog signalling in the pathogenesis and targeted therapy of melanoma. World J Clin Oncol. 2025; 16(10):105117.

[4] Crunkhorn S. Targeting the ECM in melanoma. Nat rev Drug Discov. 2025; 24(12): 906.

[5] Benito-Martin A, Nogués L, Hergueta-Redondo M, et al. Mast cells impair melanoma cell homing and metastasis by inhibiting HMGA1 secretion. Immunology. 2023; 168(2): 362-373.

[6] Rawson R, Maher N, Menzies A, et al. Pathological response calculation assessment remains accurate with reduced tumor bed examination following neoadjuvant immunotherapy in clinically detectable stage III melanoma. Ann Oncol. 2025;S0923-7534(25)06189-7.

[7] Campbell K M, Amouzgar M, Pfeiffer S M, et al. Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma. Cancer Cell. 2023, 41(4): 791–806. e4.

[8] Ghorbaninejad M, Kamrani S, Ghorbaninejad Z, et al. Epigenetic crosstalk in bone and cartilage disorders: emerging role of extracellular vesicles. Biomed Pharmacother. 2025; 193:118706.

[9] Li M, Wang Y, Zhang H, et al. The recent progress of tumor cell-derived exosomes in the pathogenesis, diagnosis and therapeutic strategies of tumors. J Transl Med. 2025; 23(1): 925.

[10] Ng JQ, Yazid NAA, Tan SC, et al. Extracellular vesicles as delivery vehicles and therapeutic agents for glioblastoma treatment: a systematic review of in vitro and in vivo preclinical studies. Asian J Pharm Sci. 2025; 20(3):101043.

[11] Yeat NY, Chen R-H. Extracellular vesicles: biogenesis mechanism and impacts on tumor immune microenvironment. J Biomed Sci 2025; 32(1): 85.

[12] Tan Y, Tang F, Li J, et al. Tumor-derived exosomes: The emerging orchestrators in melanoma. Biomed Pharmacother. 2022; 149:112832.

[13] Xie J, Zheng Z, Tuo L, et al. Recent advances in exosome-based immunotherapy applied to cancer. Front Immunol. 2023; 14:1296857.

[14] Hu Y, Li Y, Xiong H, et al. Exosomal SLC16A1-AS1-induced M2 macrophages polarization facilitates hepatocellular carcinoma progression. Int J Biol Sci. 2024; 20(11): 4341.

[15] Ye H, Wu X, Shen Y, et al. Exosomal lncRNA TUG1 derived from BMSC ameliorate collagen-induced arthritis via BLIMP1-mediated Th17/Treg balance. Int Immunopharmacol. 2024; 142:113072.

[16] Salzmann RJ, Garbin A, Gaffo E, et al. Extracellular vesicle miR-122-5p as a prognostic biomarker in pediatric classical Hodgkin lymphoma. Int J Mol Sci. 2024; 25(24):13243.

[17] Forte D, Pellegrino RM, Falvo P, et al. Parallel single-cell metabolic analysis and extracellular vesicle profiling reveal vulnerabilities with prognostic significance in acute myeloid leukemia. Nat Commun. 2024; 15(1):10878.

[18] Zafra J, Onieva JL, Oliver J, et al. Novel blood biomarkers for response prediction and monitoring of stereotactic ablative radiotherapy and immunotherapy in metastatic oligoprogressive lung cancer. Int J Mol Sci. 2024; 25(8):4533.

[19] Haigh T, Beattie H, Wade MA, et al. The use of tissue-on-chip technology to focus the search for extracellular vesicle miRNA biomarkers in thyroid disease. Int J Mol Sci. 2023; 25(1):71.

[20] Lehrich BM, Zhang J, Monga SP, et al. Battle of the biopsies: role of tissue and liquid biopsy in hepatocellular carcinoma. J Hepatol. 2024; 80(3): 515-530.

[21] Choi JH, Cho HM, Lim JH, et al. Ultrasensitive detection of PD-L1-expressing extracellular vesicles via reflection-mediated ellipsometry: from nanoscale optical modeling to immunotherapy response prediction. Small. 2025; 21(50):e07372.

[22] Huang CS, Yu DS, Jiang SS, et al. Extracellular vesicle-mediated regulation of H3C14 contributes to gemcitabine resistance in bladder cancer. J Extracell Vesicles. 2025; 14(11):e70179.

[23] Lu J, Miao F, Zhao Y, et al. Biomimetic nanovesicle vaccines derived from dendritic cells sensitized with whole tumor antigens for melanoma immunotherapy. Mater Today Bio. 2025; 35:102409.

[24] Lin J, Huang N, Li M, et al. Dendritic cell-derived exosomes driven drug co-delivery biomimetic nanosystem for effective combination of malignant melanoma immunotherapy and gene therapy. Drug Des Dev Ther. 2023; 17: 2087-2106.

[25] Li M, Sun Y, Hu C, et al. Multifunctional hydrogels for synergistic therapy of cutaneous melanoma-associated tumor recurrence and wound regeneration. Mater Today Bio. 2025; 35:102331.

[26] Long GV, Swetter SM, Menzies AM, et al. Cutaneous melanoma. Lancet. 2023; 402(10400): 485-502.

[27] Carvalho LAD, Aguiar FC, Smalley KS, et al. Acral melanoma: new insights into the immune and genomic landscape. Neoplasia. 2023; 46:100947.

[28] Lopes FC, Sleiman MG, Sebastian K, et al. UV exposure and the risk of cutaneous melanoma in skin of color: a systematic review. JAMA Dermatol. 2021; 157(2): 213-219.

[29] Davalos V, Lovell CD, Von Itter R, et al. An epigenetic switch controls an alternative NR2F2 isoform that unleashes a metastatic program in melanoma. Nat Commun. 2023; 14(1): 1867.

[30] Haugh A, Daud AI. Therapeutic strategies in BRAF V600 wild-type cutaneous melanoma. Am J Clin Dermatol. 2024; 25(3): 407-419.

[31] Delyon J, Becherirat S, Roger A, et al. PDE4D drives rewiring of the MAPK pathway in BRAF-mutated melanoma resistant to MAPK inhibitors. Cell Commun Signal. 2024; 22(1): 559.

[32] Berry D, Moldoveanu D, Rajkumar S, et al. The NF1 tumor suppressor regulates PD-L1 and immune evasion in melanoma. Cell Rep. 2025; 44(3):115365.

[33] Kreuger IZ, Slieker RC, van Groningen T, et al. Therapeutic strategies for targeting CDKN2A loss in melanoma. J Investig Dermatol. 2023; 143(1):18-25. e1.

[34] Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic melanoma. Science. 2013; 339(6122): 959-961.

[35] Liu Y, Sheikh MS. Melanoma: molecular pathogenesis and therapeutic management. Mol Cell Pharmacol. 2014; 6(3): 228.

[36] Wang P, Jia X, Lu B, et al. Erianin suppresses constitutive activation of MAPK signaling pathway by inhibition of CRAF and MEK1/2. Signal Transduct Target Ther. 2023; 8(1): 96.

[37] Deng G, Zeng F, Su J, et al. BET inhibitor suppresses melanoma progression via the noncanonical NF-κB/SPP1 pathway. Theranostics. 2020; 10(25):11428.

[38] Wei C-Y, Zhu M-X, Yang Y-W, et al. Downregulation of RNF128 activates Wnt/β-catenin signaling to induce cellular EMT and stemness via CD44 and CTTN ubiquitination in melanoma. J Hematol Oncol. 2019; 12(1): 21.

[39] Chesney J, Lewis KD, Kluger H, et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer. 2022; 10(12):e005755.

[40] Ziogas DC, Theocharopoulos C, Koutouratsas T, et al. Mechanisms of resistance to immune checkpoint inhibitors in melanoma: what we have to overcome? Cancer Treat Rev. 2023; 113:102499.

[41] Kreger BT, Liang Y, Reilly NM, et al. CFT1946 is an orally available brain-penetrant BRAFV600-mutant degrader that overcomes BRAF inhibitor resistance. Cancer Res. 2025; 86(2): 438-452.

[42] Zhang M, Xu J, Yang Z, et al. Glycolysis-inhibiting tumor cell-derived microparticles to enhance immunogenic cell death for synergistic cancer immunotherapy. Biomaterials. 2025; 328:123832.

[43] Lo JA, Kawakubo M, Juneja VR, et al. Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. Sci Transl Med. 2021; 13(581):eabd8636.

[44] Caraviello C, Nazzaro G, Tavoletti G, et al. Melanoma skin cancer: a comprehensive review of current knowledge. Cancers. 2025; 17(17):2920.

[45] Ma W, Morris S, Jamieson C. Natural killers or natural regulators? Dual roles of NK cells in checkpoint immunotherapy. Cytokine Growth Factor Rev. 2025; 86: 199-202.

[46] Durao P, Budden T, Mallela K, et al. Systemic immunosuppression from ultraviolet radiation exposure inhibits cancer immunotherapy. J Immunother Cancer. 2025; 13(10):e012527.

[47] Crowther MD, Sohlin JE, Svane IM, et al. Tumour-infiltrating lymphocyte therapy comes of age in the era of genetic engineering. Lancet Oncol. 2025; 26(11): e577-e585.

[48] Ma F, Liu X, Zhang Y, et al. Tumor extracellular vesicle–derived PD-L1 promotes T cell senescence through lipid metabolism reprogramming. Sci Transl Med. 2025; 17(785):eadm7269.

[49] Kewitz-Hempel S, Windisch N, Hause G, et al. Extracellular vesicles derived from melanoma cells induce carcinoma-associated fibroblasts via miR-92b-3p mediated downregulation of PTEN. J Extracell Vesicles. 2024; 13(9):e12509.

[50] Lee J-H, Eberhardt M, Blume K, et al. Evidence for liver and peripheral immune cells secreting tumor-suppressive extracellular vesicles in melanoma patients. EBioMedicine. 2020; 62:103119.

[51] Al Hrout A, Levesque MP, Chahwan R. Investigating the tumor-immune microenvironment through extracellular vesicles from frozen patient biopsies and 3D cultures. Front Immunol. 2023; 14:1176175.

[52] Tenchov R, Sasso JM, Wang X, et al. Exosomes-nature's lipid nanoparticles, a rising star in drug delivery and diagnostics. ACS Nano. 2022; 16(11): 17802-17846.

[53] Bader J, Brigger F, Leroux J-C. Extracellular vesicles versus lipid nanoparticles for the delivery of nucleic acids. Adv Drug Deliv Rev. 2024; 215:115461.

[54] Kumar MA, Baba SK, Sadida HQ, et al. Extracellular vesicles as tools and targets in therapy for diseases. Signal Transduct Target Ther. 2024; 9(1): 27.

[55] Joshi BS, de Beer MA, Giepmans BN, et al. Endocytosis of extracellular vesicles and release of their cargo from endosomes. ACS Nano. 2020; 14(4): 4444-4455.

[56] Van Niel G, d'Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018; 19(4): 213-228.

[57] Ou Q, Huang W, Wang B, et al. Apoptotic vesicles: therapeutic mechanisms and critical issues. J Dent Res. 2024; 103(11): 1057-1065.

[58] Olofsson Bagge R, Berndtsson J, Urzì O, et al. Three-dimensional reconstruction of interstitial extracellular vesicles in human liver as determined by electron tomography. J Extracell Vesicles. 2023; 12(12):12380.

[59] Khalyfa A, Trzepizur W, Gileles-Hillel A, et al. Heterogeneity of melanoma cell responses to sleep apnea-derived plasma exosomes and to intermittent hypoxia. Cancers. 2021; 13(19):4781.

[60] Suman S, Nevala WK, Leontovich AA, et al. Melanoma-derived extracellular vesicles induce CD36-mediated pre-metastatic niche. Biomolecules. 2024; 14(7):837.

[61] Agüera-Lorente A, Alonso-Pardavila A, Larrinaga M, et al. Small extracellular vesicle-based human melanocyte and melanoma signature. Pigment Cell Melanoma Res. 2024; 37(5): 569-582.

[62] Parikh R, Parikh S, Berzin D, et al. Recycled melanoma-secreted melanosomes regulate tumor-associated macrophage diversification. EMBO J. 2024; 43(17): 3553-3586.

[63] Zhou M, Li YJ, Tang YC, et al. Apoptotic bodies for advanced drug delivery and therapy. J Control Release. 2022; 351: 394-406.

[64] Peruzzu D, Boussadia Z, Fratini F, et al. Inhibition of cholesterol transport impairs Cav-1 trafficking and small extracellular vesicles secretion, promoting amphisome formation in melanoma cells. Traffic. 2023; 24(2): 76-94.

[65] Luo M, Zhu J, Ren J, et al. Lactate increases tumor malignancy by promoting tumor small extracellular vesicles production via the GPR81-cAMP-PKA-HIF-1α axis. Front Oncol. 2022; 12:1036543.

[66] Liu C, Liu D, Wang S, et al. Identification of the SNARE complex that mediates the fusion of multivesicular bodies with the plasma membrane in exosome secretion. J Extracell Vesicles. 2023; 12(9):12356.

[67] Carney RP, Mizenko RR, Bozkurt BT, et al. Harnessing extracellular vesicle heterogeneity for diagnostic and therapeutic applications. Nat Nanotechnol. 2025; 20(1): 14-25.

[68] Karbanová J, Deniz IA, Wilsch-Bräuninger M, et al. Extracellular lipidosomes containing lipid droplets and mitochondria are released during melanoma cell division. Cell Commun Signal. 2024; 22(1): 57.

[69] Irmer B, Efing J, Reitnauer LE, et al. Extracellular vesicle-associated tyrosine kinase-like orphan receptors ROR1 and ROR2 promote breast cancer progression. Cell Commun Signal. 2023; 21(1): 171.

[70] Hurley JH, Coyne AN, Miączyńska M, et al. The expanding repertoire of ESCRT functions in cell biology and disease. Nature. 2025; 642(8069): 877-888.

[71] Choi D, Montermini L, Kim DK, et al. The impact of oncogenic EGFRvIII on the proteome of extracellular vesicles released from glioblastoma cells. Mol Cell Proteom. 2018; 17(10): 1948-1964.

[72] Al-Nedawi K, Meehan B, Micallef J, et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol. 2008; 10(5): 619-624.

[73] Lee H, Li C, Zhang Y, et al. Caveolin-1 selectively regulates microRNA sorting into microvesicles after noxious stimuli. J Exp Med. 2019; 216(9): 2202-2220.

[74] Wozniak AL, Adams A, King KE, et al. The RNA binding protein FMR1 controls selective exosomal miRNA cargo loading during inflammation. J Cell Biol. 2020; 219(10):e201912074.

[75] Cha DJ, Franklin JL, Dou Y, et al. KRAS-dependent sorting of miRNA to exosomes. Elife. 2015; 4:e07197.

[76] McKenzie AJ, Hoshino D, Hong NH, et al. KRAS-MEK signaling controls Ago2 sorting into exosomes. Cell Rep. 2016; 15(5): 978-987.

[77] Ali A, Zambrano R, Duncan MR, et al. Hyperoxia-activated circulating extracellular vesicles induce lung and brain injury in neonatal rats. Sci Rep. 2021; 11(1): 8791.

[78] Zhu J, Lu K, Zhang N, et al. Myocardial reparative functions of exosomes from mesenchymal stem cells are enhanced by hypoxia treatment of the cells via transferring microRNA-210 in an nSMase2-dependent way. Artif Cells Nanomed Biotechnol. 2018; 46(8): 1659-1670.

[79] van Niel G, Carter DR, Clayton A, et al. Challenges and directions in studying cell–cell communication by extracellular vesicles. Nat Rev Mol Cell Biol. 2022; 23(5): 369-382.

[80] Crescitelli R, Filges S, Karimi N, et al. Extracellular vesicle DNA from human melanoma tissues contains cancer-specific mutations. Front Cell Dev Biol. 2022; 10:1028854.

[81] Zocco D, Bernardi S, Novelli M, et al. Isolation of extracellular vesicles improves the detection of mutant DNA from plasma of metastatic melanoma patients. Sci Rep. 2020; 10(1):15745.

[82] García-Silva S, Benito-Martín A, Sánchez-Redondo S, et al. Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and BRAF V600E mutation. J Exp Med. 2019; 216(5): 1061-1070.

[83] Shu S, Matsuzaki J, Want MY, et al. An immunosuppressive effect of melanoma-derived exosomes on NY-ESO-1 antigen-specific human CD8⁺ T cells is dependent on IL-10 and independent of BRAFV600E mutation in melanoma cell lines. Immunol Investig. 2020; 49(7): 744-757.

[84] Samuels M, Karakostas C, Besta S, et al. LMTK3 regulation of EV biogenesis and cargo sorting promotes tumour growth by reducing monocyte infiltration and driving pro-tumourigenic macrophage polarisation in breast cancer. Mol Cancer. 2025; 24(1): 149.

[85] Ostrowski M, Carmo NB, Krumeich S, et al. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol. 2010; 12(1): 19-30.

[86] Kosaka N, Iguchi H, Hagiwara K, et al. Neutral sphingomyelinase 2 (nSMase2)-dependent exosomal transfer of angiogenic microRNAs regulate cancer cell metastasis. J Biol Chem. 2013; 288(15): 10849-10859.

[87] Villarroya-Beltri C, Gutiérrez-Vázquez C, Sánchez-Cabo F, et al. Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs. Nat Commun. 2013; 4(1): 2980.

[88] Rani S, Lai A, Nair S, et al. Extracellular vesicles as mediators of cell-cell communication in ovarian cancer and beyond–a lipids focus. Cytokine Growth Factor Rev. 2023; 73: 52-68.

[89] Sakurai Y, Ohtani A, Nakayama Y, et al. Logistics and distribution of small extracellular vesicles from the subcutaneous space to the lymphatic system. J Control Release. 2023; 361: 77-86.

[90] Fabbiano F, Corsi J, Gurrieri E, et al. RNA packaging into extracellular vesicles: an orchestra of RNA-binding proteins? J Extracell Vesicles. 2020; 10(2):e12043.

[91] Shen Y, Li M, Liao L, et al. Plasma exosome-derived connexin43 as a promising biomarker for melanoma patients. BMC Cancer. 2023; 23(1): 242.

[92] Amor López A, Mazariegos MS, Capuano A, et al. Inactivation of EMILIN-1 by proteolysis and secretion in small extracellular vesicles favors melanoma progression and metastasis. Int J Mol Sci. 2021; 22(14):7406.

[93] Sun L, Wei X, Zhao Q, et al. Dynamic change of PD-L2 on circulating plasma extracellular vesicles as a predictor of treatment response in melanoma patients receiving anti-PD-1 therapy. J Extracell Vesicles. 2025; 14(4):e70054.

[94] Serratì S, Guida M, Di Fonte R, et al. Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma. Mol Cancer. 2022; 21(1): 20.

[95] Paolino G, Huber V, Camerini S, et al. The fatty acid and protein profiles of circulating CD81-positive small extracellular vesicles are associated with disease stage in melanoma patients. Cancers. 2021; 13(16):4157.

[96] Wang M, Jia J, Cui Y, et al. CD73-positive extracellular vesicles promote glioblastoma immunosuppression by inhibiting T-cell clonal expansion. Cell Death Dis. 2021; 12(11): 1065.

[97] Salviano-Silva A, Wollmann K, Brenna S, et al. Extracellular vesicles carrying tenascin-C are clinical biomarkers and improve tumor-derived DNA analysis in glioblastoma patients. ACS Nano. 2025; 19(10): 9844-9859.

[98] Yao X, He D, Wei P, et al. DNA nanomaterial-empowered surface engineering of extracellular vesicles. Adv Mater. 2024; 36(37):2306852.

[99] Casanova-Salas I, Aguilar D, Cordoba-Terreros S, et al. Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomics and transcriptomic evolution. Cancer Cell. 2024; 42(7):1301-1312. e7.

[100] Wang K, Wang X, Pan Q, et al. Liquid biopsy techniques and pancreatic cancer: diagnosis, monitoring, and evaluation. Mol Cancer. 2023; 22(1): 167.

[101] Lian Q, Xu J, Yan S, et al. Chemotherapy-induced intestinal inflammatory responses are mediated by exosome secretion of double-strand DNA via AIM2 inflammasome activation. Cell Res. 2017; 27(6): 784-800.

[102] Matsumoto A, Takahashi Y, Ariizumi R, et al. Development of DNA-anchored assembly of small extracellular vesicle for efficient antigen delivery to antigen presenting cells. Biomaterials. 2019; 225:119518.

[103] You Y, Tian Y, Yang Z, et al. Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy. Nat Biomed Eng. 2023; 7(7): 887-900.

[104] Jorge GP, Gontijo M, Silva MFre, et al. Violacein-loaded outer membrane vesicles from Salmonella enterica exhibit potent anti-melanoma activity in vitro and in vivo. ACS Biomater Sci Eng. 2025; 11(10): 6166-6184.

[105] Schiera G, Di Liegro CM, Puleo V, et al. Extracellular vesicles shed by melanoma cells contain a modified form of H1.0 linker histone and H1.0 mRNA-binding proteins. Int J Oncol. 2016; 49(5): 1807-1814.

[106] Zickler AM, Liang X, Gupta D, et al. Novel endogenous engineering platform for robust loading and delivery of functional mRNA by extracellular vesicles. Adv Sci. 2024; 11(42):2407619.

[107] Luo X, McAndrews KM, Arian KA, et al. Development of an engineered extracellular vesicles-based vaccine platform for combined delivery of mRNA and protein to induce functional immunity. J Control Release. 2024; 374: 550-562.

[108] Bychkov ML, Kirichenko AV, Mikhaylova IN, et al. Extracellular vesicles derived from metastatic melanoma cells transferα7-nAChR mRNA, thus increasing the surface expression of the receptor and stimulating the growth of normal keratinocytes. Acta Nat. 2022; 14(3): 95.

[109] Crucitta S, Cucchiara F, Marconcini R, et al. TGF-β mRNA levels in circulating extracellular vesicles are associated with response to anti-PD1 treatment in metastatic melanoma. Front Mol Biosci. 2024; 11:1288677.

[110] Lattmann E, Levesque MP. The role of extracellular vesicles in melanoma progression. Cancers. 2022; 14(13):3086.

[111] Bychkov ML, Kirichenko AV, Mikhaylova IN, et al. Extracellular vesicles derived from acidified metastatic melanoma cells stimulate growth, migration, and stemness of normal keratinocytes. Biomedicines. 2022; 10(3):660.

[112] Luan W, Lu X, Peng H, et al. Exosomal miR-19a derived from melanoma cell promotes the vemurafenib resistance of malignant melanoma through directly targeting LRIG1 to reactivate AKT and MAPK pathway. Pathol-Res Pract. 2024; 260:155410.

[113] Zhou E, Li Y, Wu F, et al. Circulating extracellular vesicles are effective biomarkers for predicting response to cancer therapy. EBioMedicine. 2021; 67:103365.

[114] Kingreen T, Kewitz-Hempel S, Rohde C, et al. Extracellular vesicles from highly invasive melanoma subpopulations increase the invasive capacity of less invasive melanoma cells through mir-1246-mediated inhibition of CCNG2. Cell Commun Signal. 2024; 22(1): 442.

[115] Rigg E, Wang J, Xue Z, et al. Inhibition of extracellular vesicle-derived miR-146a-5p decreases progression of melanoma brain metastasis via Notch pathway dysregulation in astrocytes. J Extracell Vesicles. 2023; 12(10):12363.

[116] Gajos-Michniewicz A, Duechler M, Czyz M. MiRNA in melanoma-derived exosomes. Cancer Lett. 2014; 347(1): 29-37.

[117] Santos NL, Bustos SO, Reis PP, et al. Extracellular vesicle-packaged miR-195-5p sensitizes melanoma to targeted therapy with kinase inhibitors. Cells. 2023; 12(9):1317.

[118] Zeng B, Chen Y, Chen H, et al. Synergistic inhibition of NUDT21 by secretory S100A11 and exosomal miR-487a-5p promotes melanoma oligo-to poly-metastatic progression. Mol Oncol. 2023; 17(12): 2743-2766.

[119] Luan W, Ding Y, Xi H, et al. Exosomal miR-106b-5p derived from melanoma cell promotes primary melanocytes epithelial-mesenchymal transition through targeting EphA4. J Exp Clin Cancer Res. 2021; 40(1): 107.

[120] Hino Y, Arif M, Rahman MM, et al. Hypoxia-mediated long non-coding RNA fragment identified in canine oral melanoma through transcriptome analysis. Vet Sci. 2024; 11(8):361.

[121] Pan Y, Lu X, Shu G, et al. Extracellular vesicle-mediated transfer of LncRNA IGFL2-AS1 confers sunitinib resistance in renal cell carcinoma. Cancer Res. 2023; 83(1): 103-116.

[122] Zhao H, Jiang R, Zhang C, et al. LncRNA H19-rich extracellular vesicles derived from gastric cancer stem cells facilitate tumorigenicity and metastasis via mediating intratumor communication network. J Transl Med. 2023; 21(1): 238.

[123] Chen Y, Zhang Y-H, Li J, et al. Novel lncRNA Gm33149 modulates metastatic heterogeneity in melanoma by regulating the miR-5623-3p/Wnt axis via exosomal transfer. Cancer Gene Ther. 2024; 31(3): 364-375.

[124] Xiang M, Li Z, Su J, et al. KLF12 transcriptional activation by a novel LncRNA A930015D03Rik enhances melanoma metastasis. Int J Biol Macromol. 2025; 309:142686.

[125] Yao H, Huang C, Zou J, et al. Extracellular vesicle-packaged lncRNA from cancer-associated fibroblasts promotes immune evasion by downregulating HLA-A in pancreatic cancer. J Extracell Vesicles. 2024; 13(7):e12484.

[126] Ding Z, Wu B, Yang J, et al. Glycolysis regulated exosomal LINC01214 inhibited CD8⁺ T cell function and induced anti-PD1 resistance in melanoma via modulating miR-4492/PPP1R11 axis. Non-Coding RNA Res. 2025; 10: 242-251.

[127] Hu T, Hu J. Melanoma-derived exosomes induce reprogramming fibroblasts into cancer-associated fibroblasts via Gm26809 delivery. Cell Cycle. 2019; 18(22): 3085-3094.

[128] Kristensen LS, Ebbesen KK, Sokol M, et al. Spatial expression analyses of the putative oncogene ciRS-7 in cancer reshape the microRNA sponge theory. Nat Commun. 2020; 11(1): 4551.

[129] Zhang F, Jiang J, Qian H, et al. Exosomal circRNA: emerging insights into cancer progression and clinical application potential. J Hematol Oncol. 2023; 16(1): 67.

[130] Zhou J, Song Q, Li H, et al. Targeting circ-0034880-enriched tumor extracellular vesicles to impede SPP1highCD206⁺ pro-tumor macrophages mediated pre-metastatic niche formation in colorectal cancer liver metastasis. Mol Cancer. 2024; 23(1): 168.

[131] Li C, Ni Y-Q, Xu H, et al. Roles and mechanisms of exosomal non-coding RNAs in human health and diseases. Signal Transduct Target Ther. 2021; 6(1): 383.

[132] Ho JS, Di Tullio F, Schwarz M, et al. HNRNPM controls circRNA biogenesis and splicing fidelity to sustain cancer cell fitness. Elife. 2021; 10:e59654.

[133] Hu Z, Chen G, Zhao Y, et al. Exosome-derived circCCAR1 promotes CD8⁺ T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma. Mol Cancer. 2023; 22(1): 55.

[134] Zhu H, Zhang P, Shi J, et al. Exosome-delivered circRPS5 inhibits the progression of melanoma via regulating the miR-151a/NPTX1 axis. Plos One. 2023; 18(6):e0287347.

[135] Wang X, Cheng Q. Suppression of exosomal hsa_circ_0001005 eliminates the vemurafenib resistance of melanoma. J Cancer Res Clin Oncol. 2023; 149(9): 5921-5936.

[136] Wu N, Yuan Z, Du KY, et al. Translation of yes-associated protein (YAP) was antagonized by its circular RNA via suppressing the assembly of the translation initiation machinery. Cell Death Differ. 2019; 26(12): 2758-2773.

[137] Wang L, Shen K, Gao Z, et al. Melanoma derived exosomes amplify radiotherapy induced abscopal effect via IRF7/I-IFN axis in macrophages. Adv Sci. 2024; 11(13):2304991.

[138] Espiau-Romera P, Gordo-Ortiz A, Ortiz-de-Solórzano I, et al. Metabolic features of tumor-derived extracellular vesicles: challenges and opportunities. Extracell Vesicles Circ Nucleic Acids. 2024; 5(3): 455.

[139] Stanly C, Alfieri M, Ambrosone A, et al. Grapefruit-derived micro and nanovesicles show distinct metabolome profiles and anticancer activities in the A375 human melanoma cell line. Cells. 2020; 9(12):2722.

[140] Bollard S, Howard J, Casalou C, et al. Proteomic and metabolomic profiles of plasma-derived extracellular vesicles differentiate melanoma patients from healthy controls. Transl Oncol. 2024; 50:102152.

[141] Liu Z, Wang D, Zhang J, et al. cGAS-STING signaling in the tumor microenvironment. Cancer Lett. 2023; 577:216409.

[142] Chen QY, Gao B, Tong D, et al. Crosstalk between extracellular vesicles and tumor-associated macrophage in the tumor microenvironment. Cancer Lett. 2023; 552:215979.

[143] Chen J, Tang T-T, Cao J-Y, et al. KIM-1 augments hypoxia-induced tubulointerstitial inflammation through uptake of small extracellular vesicles by tubular epithelial cells. Mol Ther. 2023; 31(5): 1437-1450.

[144] Wan H, Zhong L, Xia T, et al. Silencing exosomal circ102927 inhibits foot melanoma metastasis via regulating invasiveness, epithelial-mesenchymal transition and apoptosis. Cancer Manag Res. 2024; 16: 825-839.

[145] Luo X, Kugeratski FG, Dowlatshahi DP, et al. Engineered immunomodulatory extracellular vesicles from epithelial cells with the capacity for stimulation of innate and adaptive immunity in cancer and autoimmunity. ACS Nano. 2025; 19(5): 5193-5216.

[146] Fane ME, Chhabra Y, Alicea GM, et al. Stromal changes in the aged lung induce an emergence from melanoma dormancy. Nature. 2022; 606(7913): 396-405.

[147] Strnadová K, Pfeiferová L, Přikryl P, et al. Exosomes produced by melanoma cells significantly influence the biological properties of normal and cancer-associated fibroblasts. Histochem Cell Biol. 2022; 157(2): 153-172.

[148] Tang H, Zhou X, Zhao X, et al. HSP90/IKK-rich small extracellular vesicles activate pro-angiogenic melanoma-associated fibroblasts via the NF-κB/CXCL1 axis. Cancer Sci. 2022; 113(4): 1168-1181.

[149] Guo Y, Wang H, Liu S, et al. Engineered extracellular vesicles with DR5 agonistic scFvs simultaneously target tumor and immunosuppressive stromal cells. Sci Adv. 2025; 11(3):eadp9009.

[150] Xie J, Lin X, Deng X, et al. Cancer-associated fibroblast-derived extracellular vesicles: regulators and therapeutic targets in the tumor microenvironment. Cancer Drug Resist. 2025; 8:2.

[151] Hüser L, Chhabra Y, Gololobova O, et al. Aged fibroblast-derived extracellular vesicles promote angiogenesis in melanoma. Cell Rep. 2024; 43(9):114721.

[152] Fujii N, Yashiro M, Hatano T, et al. CD9-positive exosomes derived from cancer-associated fibroblasts might inhibit the proliferation of malignant melanoma cells. Anticancer Res. 2023; 43(1): 25-33.

[153] Orso F, Virga F, Dettori D, et al. Stroma-derived miR-214 coordinates tumor dissemination. J Exp Clin Cancer Res. 2023; 42(1): 20.

[154] Zi SF, Wu XJ, Tang Y, et al. Endothelial cell-derived extracellular vesicles promote aberrant neutrophil trafficking and subsequent remote lung injury. Adv Sci. 2024; 11(38):2400647.

[155] Surman M, Wilczak M, Bzowska M, et al. The proangiogenic effects of melanoma-derived ectosomes are mediated byαvβ5 integrin rather than αvβ3 integrin. Cells. 2024; 13(16):1336.

[156] Morimoto M, Maishi N, Tsumita T, et al. miR-1246 in tumor extracellular vesicles promotes metastasis via increased tumor cell adhesion and endothelial cell barrier destruction. Front Oncol. 2023; 13:973871.

[157] Torii C, Maishi N, Kawamoto T, et al. miRNA-1246 in extracellular vesicles secreted from metastatic tumor induces drug resistance in tumor endothelial cells. Sci Rep. 2021; 11(1):13502.

[158] García-Silva S, Benito-Martín A, Nogués L, et al. Melanoma-derived small extracellular vesicles induce lymphangiogenesis and metastasis through an NGFR-dependent mechanism. Nat Cancer. 2021; 2(12): 1387-1405.

[159] Wilczak M, Surman M, Przybyło M. Melanoma-derived extracellular vesicles transfer proangiogenic factors. Oncol Res. 2025; 33(2): 245.

[160] Leary N, Walser S, He Y, et al. Melanoma-derived extracellular vesicles mediate lymphatic remodelling and impair tumour immunity in draining lymph nodes. J Extracell Vesicles. 2022; 11(2):e12197.

[161] Castro MV, Barbero GA, Máscolo P, et al. ROR2 increases the chemoresistance of melanoma by regulating p53 and Bcl2-family proteins via ERK hyperactivation. Cell Mol Biol Lett. 2022; 27(1): 23.

[162] Palacios-Ferrer JL, García-Ortega MB, Gallardo-Gómez M, et al. Metabolomic profile of cancer stem cell-derived exosomes from patients with malignant melanoma. Mol Oncol. 2021; 15(2): 407-428.

[163] Kim J, Zhu Y, Chen S, et al. Anti-glioma effect of ginseng-derived exosomes-like nanoparticles by active blood–brain-barrier penetration and tumor microenvironment modulation. J Nanobiotechnology. 2023; 21(1): 253.

[164] Shi L, Li B, Zhang Y, et al. Exosomal lncRNA Mir100hg derived from cancer stem cells enhance glycolysis and promote metastasis of lung adenocarcinoma through mircroRNA-15a-5p/31-5p. Cell Commun Signal. 2023; 21(1): 248.

[165] Zhang Y, Chen Y, Shi L, et al. Extracellular vesicles microRNA-592 of melanoma stem cells promotes metastasis through activation of MAPK/ERK signaling pathway by targeting PTPN7 in non-stemness melanoma cells. Cell Death Discov. 2022; 8(1): 428.

[166] Liu D, Li X, Zeng B, et al. Exosomal microRNA-4535 of melanoma stem cells promotes metastasis by inhibiting autophagy pathway. Stem Cell Rev Rep. 2023; 19(1): 155-169.

[167] Yang C, Wu S, Mou Z, et al. Exosome-derived circTRPS1 promotes malignant phenotype and CD8⁺ T cell exhaustion in bladder cancer microenvironments. Mol Ther. 2022; 30(3): 1054-1070.

[168] Dan Y, Ma J, Long Y, et al. Melanoma extracellular vesicles inhibit tumor growth and metastasis by stimulating CD8 T cells. Mol Immunol. 2024; 169: 78-85.

[169] Yang E, Wang X, Gong Z, et al. Exosome-mediated metabolic reprogramming: the emerging role in tumor microenvironment remodeling and its influence on cancer progression. Signal Transduct Target Ther. 2020; 5(1): 242.

[170] Shin S, Jung I, Jung D, et al. Novel antitumor therapeutic strategy using CD4⁺ T cell-derived extracellular vesicles. Biomaterials. 2022; 289:121765.

[171] Wolf S, Madanchi M, Turko P, et al. Anti-CTLA4 treatment reduces lymphedema risk potentially through a systemic expansion of the FOXP3⁺ Treg population. Nat Commun. 2024; 15(1):10784.

[172] Li T, Wu T, Li X, et al. Transcriptional switches in melanoma T cells: facilitating polarizing into regulatory T cells. Int Immunopharmacol. 2024; 137:112484.

[173] Gamboa L, Zamat AH, Thiveaud CA, et al. Sensitizing solid tumors to CAR-mediated cytotoxicity by lipid nanoparticle delivery of synthetic antigens. Nat Cancer. 2025; 6(6): 1073-1087.

[174] Zhong W, Xiao Z, Qin Z, et al. Tumor-derived small extracellular vesicles inhibit the efficacy of CAR T cells against solid tumors. Cancer Res. 2023; 83(16): 2790-2806.

[175] Kim J, Kim T-J, Chae S, et al. Targeted deletion of CD244 on monocytes promotes differentiation into anti-tumorigenic macrophages and potentiates PD-L1 blockade in melanoma. Mol Cancer. 2024; 23(1): 45.

[176] Wiklander OP, Mamand DR, Mohammad DK, et al. Antibody-displaying extracellular vesicles for targeted cancer therapy. Nat Biomed Eng. 2024; 8(11): 1453-1468.

[177] Lee H, Ferguson AL, Quek C, et al. Intratumoral CD16⁺ macrophages are associated with clinical outcomes of patients with metastatic melanoma treated with combination anti-PD-1 and anti-CTLA-4 therapy. Clin Cancer Res. 2023; 29(13): 2513-2524.

[178] Blavier L, Nakata R, Neviani P, et al. The capture of extracellular vesicles endogenously released by xenotransplanted tumours induces an inflammatory reaction in the premetastatic niche. J Extracell Vesicles. 2023; 12(5):12326.

[179] Suman S, Nevala WK, Leontovich AA, et al. Melanoma-derived cytokines and extracellular vesicles are interlinked with macrophage immunosuppression. Front Mol Biosci. 2025; 11:1522717.

[180] Huang L, Yang J, Zhu J, et al. Programmed death ligand-1 in melanoma and extracellular vesicles promotes local and regional immune suppression through M2-like macrophage polarization. Am J Pathol. 2025; 195(2): 306-320.

[181] Andreucci E, Ruzzolini J, Bianchini F, et al. miR-214-Enriched extracellular vesicles released by acid-adapted melanoma cells promote inflammatory macrophage-dependent tumor trans-endothelial migration. Cancers. 2022; 14(20):5090.

[182] Ren Z, Xu Z, Chang X, et al. STC1 competitively bindingβPIX enhances melanoma progression via YAP nuclear translocation and M2 macrophage recruitment through the YAP/CCL2/VEGFA/AKT feedback loop. Pharmacol Res. 2024; 204: 107218.

[183] Han S, Wang W, Wang S, et al. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes. Theranostics. 2021; 11(6): 2892.

[184] Zhong W, Lu Y, Han X, et al. Upregulation of exosome secretion from tumor-associated macrophages plays a key role in the suppression of anti-tumor immunity. Cell Rep. 2023; 42(10):113224.

[185] Mahmoudian M, Alizadeh S, Lotfi D, et al. Modulating exosomal communication between macrophages and melanoma cancer cells via cyclodextrin-based nanosponges loaded with doxorubicin. Nanotoxicology. 2025; 19(1): 17-27.

[186] Wu P, Guo Y, Xiao L, et al. LILRB2-containing small extracellular vesicles from glioblastoma promote tumor progression by promoting the formation and expansion of myeloid-derived suppressor cells. Cancer Immunol Immunother. 2023; 72(7): 2179-2193.

[187] Arkhypov I, Kurt FGÖ, Bitsch R, et al. HSP90α induces immunosuppressive myeloid cells in melanoma via TLR4 signaling. J Immunother Cancer. 2022; 10(9):e005551.

[188] Lasser S, Ozbay Kurt FG, Fritz L, et al. Generation of myeloid-derived suppressor cells mediated by microRNA-125a-5p in melanoma. Int J Mol Sci. 2024; 25(12):6693.

[189] Mamand DR, Bazaz S, Mohammad DK, et al. Extracellular vesicles originating from melanoma cells promote dysregulation in haematopoiesis as a component of cancer immunoediting. J Extracell Vesicles. 2024; 13(7):e12471.

[190] Han J, Qin R, Zheng S, et al. MSC microvesicles loaded G-quadruplex-enhanced circular single-stranded DNA-9 inhibits tumor growth by targeting MDSCs. J Nanobiotechnology. 2024; 22(1): 237.

[191] Coleborn E, Ghebosu R, Wolfram J, et al. Cancer-derived extracellular vesicles in natural killer cell immune evasion: molecular mechanisms and therapeutic insights. Mol Ther. 2025; 33(9): 4113-4129.

[192] Federici C, Shahaj E, Cecchetti S, et al. Natural-killer-derived extracellular vesicles: immune sensors and interactors. Front Immunol. 2020; 11:262.

[193] Zhu L, Kalimuthu S, Gangadaran P, et al. Exosomes derived from natural killer cells exert therapeutic effect in melanoma. Theranostics. 2017; 7(10): 2732.

[194] Aarsund M, Segers FM, Wu Y, et al. Comparison of characteristics and tumor targeting properties of extracellular vesicles derived from primary NK cells or NK-cell lines stimulated with IL-15 or IL-12/15/18. Cancer Immunol Immunother. 2022; 71(9): 2227-2238.

[195] Wu J, Wu D, Wu G, et al. Scale-out production of extracellular vesicles derived from natural killer cells via mechanical stimulation in a seesaw-motion bioreactor for cancer therapy. Biofabrication. 2022; 14(4):045004.

[196] Jella KK, Nasti TH, Li Z, et al. Exosome-containing preparations from postirradiated mouse melanoma cells delay melanoma growth in vivo by a natural killer cell–dependent mechanism. Int J Radiat Oncol Biol Phys. 2020; 108(1): 104-114.

[197] Komarova EY, Suezov RV, Nikotina AD, et al. Hsp70-containing extracellular vesicles are capable of activating of adaptive immunity in models of mouse melanoma and colon carcinoma. Sci Rep. 2021; 11(1):21314.

[198] Mi X, Duan Y, Sun J, et al. The ketogenic diet modulates tumor-associated neutrophil polarization via the AMOT-YAP/TAZ axis to inhibit colorectal cancer progression. Pharmacol Res. 2024; 210:107494.

[199] Guimarães-Bastos D, Frony AC, Barja-Fidalgo C, et al. Melanoma-derived extracellular vesicles skew neutrophils into a pro-tumor phenotype. J Leukoc Biol. 2022; 111(3): 585-596.

[200] Chen S, Luo Y, He Y, et al. In-situ-sprayed therapeutic hydrogel for oxygen-actuated Janus regulation of postsurgical tumor recurrence/metastasis and wound healing. Nat Commun. 2024; 15(1): 814.

[201] Su L-Y, Tian Y, Zheng Q, et al. Anti-tumor immunotherapy using engineered bacterial outer membrane vesicles fused to lysosome-targeting chimeras mediated by transferrin receptor. Cell Chem Biol. 2024; 31(6):1219-1230. e5.

[202] Park KS, Svennerholm K, Crescitelli R, et al. Synthetic bacterial vesicles combined with tumour extracellular vesicles as cancer immunotherapy. J Extracell Vesicles. 2021; 10(9):e12120.

[203] Cheng K, Zhao R, Li Y, et al. Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via Plug-and-Display technology. Nat Commun. 2021; 12(1): 2041.

[204] Zhou Q, Yan Y, Li Y, et al. Tumor-derived extracellular vesicles in melanoma immune response and immunotherapy. Biomed Pharmacother. 2022; 156:113790.

[205] Lee D, Cho M, Kim E, et al. PD-L1: From cancer immunotherapy to therapeutic implications in multiple disorders. Mol Ther. 2024; 32(12): 4235-4255.

[206] Shi X, Zhao X, He Y, et al. Posttranslational remodeling micelle reverses cell-surface and exosomal PD-L1 immunosuppression in tumors resistant to PD-L1 antibody therapy. J Control Release. 2025; 384:113961.

[207] Wu Y, Zhou L, Zou Y, et al. Disrupting the phase separation of KAT8–IRF1 diminishes PD-L1 expression and promotes antitumor immunity. Nat Cancer. 2023; 4(3): 382-400.

[208] Chen G, Huang AC, Zhang W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018; 560(7718): 382-386.

[209] Chen Y, Wang X, Li H, et al. Oncoprotein SND1-enriched exosomes facilitate melanoma lung metastasis by regulating CD47-SIRPα-mediated macrophage reprogramming. Cancer Lett. 2025; 634:218037.

[210] Dieterich LC. Mechanisms of extracellular vesicle-mediated immune evasion in melanoma. Front Immunol. 2022; 13:1002551.

[211] Lee JH, Song J, Kim IG, et al. Exosome-mediated delivery of transforming growth factor-β receptor 1 kinase inhibitors and toll-like receptor 7/8 agonists for combination therapy of tumors. Acta Biomater. 2022; 141: 354-363.

[212] Hsu C-Y, Chandramoorthy HC, Mohammed JS, et al. Exosomes as key mediators in immune and cancer cell interactions: insights in melanoma progression and therapy. Arch Dermatol Res. 2025; 317(1): 729.

[213] Chen W. TGF-β regulation of T cells. Annu Rev Immunol. 2023; 41(1): 483-512.

[214] Raimondo S, Pucci M, Alessandro R, et al. Extracellular vesicles and tumor-immune escape: biological functions and clinical perspectives. Int J Mol Sci. 2020; 21(7):2286.

[215] Lubrano S, Cervantes-Villagrana RD, Faraji F, et al. FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma. Cancer Cell. 2025; 43(3):428-445. e6.

[216] López-Borrego S, Campos-Silva C, Sandúa A, et al. MAPK inhibitors dynamically affect melanoma release of immune NKG2D-ligands, as soluble protein and extracellular vesicle-associated. Front Cell Dev Biol. 2023; 10:1055288.

[217] Tehranian C, Fankhauser L, Harter PN, et al. The PI3K/Akt/mTOR pathway as a preventive target in melanoma brain metastasis. Neuro-Oncol. 2022; 24(2): 213-225.

[218] Lidsky M, Antoun G, Speicher P, et al. Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells. J Biol Chem. 2014; 289(40): 27714-27726.

[219] Chen Y, Zeng B, Xiang M, et al. The exosomal miRNA-3184-3p derived from highly metastatic melanoma cells promotes metastatic competency via the positive feedback loop of NLK/Wnt/S100A11. Biochem Pharmacol. 2025; 240:117086.

[220] Ghezzi B, Fiorilla I, Carreira Á, et al. NAMPT and NNMT released via extracellular vesicles and as soluble mediators are distinguished traits of BRAF inhibitor resistance of melanoma cells impacting on the tumor microenvironment. Cell Commun Signal. 2025; 23(1): 348.

[221] Roccuzzo G, Sarda C, Pala V, et al. Prognostic biomarkers in melanoma: a 2023 update from clinical trials in different therapeutic scenarios. Expert Rev Mol Diagn. 2024; 24(5): 379-392.

[222] Słomka A, Wang B, Mocan T, et al. Extracellular vesicles and circulating tumour cells-complementary liquid biopsies or standalone concepts? Theranostics. 2022; 12(13): 5836.

[223] Lee H, Liao J-D, Wong T-W, et al. Detection of micro-plasma-induced exosomes secretion in a fibroblast-melanoma co-culture model. Anal Chim Acta. 2023; 1281:341910.

[224] Shen H, Atiyas Y, Yang Z, et al. Ultrasensitive quantification of PD-L1⁺ extracellular vesicles in melanoma patient plasma using a parallelized high throughput droplet digital assay. Lab Chip. 2024; 24(14): 3403-3411.

[225] Van Laar R, Latif B, King S, et al. Validation of a microRNA liquid biopsy assay for diagnosis and risk stratification of invasive cutaneous melanoma. Br J Dermatol. 2023; 189(3): 292-301.

[226] De Martino E, Gandin I, Azzalini E, et al. A group of three miRNAs can act as candidate circulating biomarkers in liquid biopsies from melanoma patients. Front Med. 2023; 10:1180799.

[227] Hasan MN, Rahman MM, Husna AA, et al. Hypoxia-related Y RNA fragments as a novel potential biomarker for distinguishing metastatic oral melanoma from non-metastatic oral melanoma in dogs. Vet Q. 2024; 44(1): 1-8.

[228] Smith SM, Kumari A, Marvar JP, et al. Stellate silicon microneedles for rapid point-of-care melanoma exosome isolation and detection via a lateral flow assay. Biosens Bioelectron. 2025; 285:117560.

[229] Welsh JA, Goberdhan DC, O'Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J Extracell Vesicles. 2024; 13(2):e12404.

[230] Chen X, Shen J, Liu C, et al. Applications of data characteristic AI-assisted Raman spectroscopy in pathological classification. Anal Chem. 2024; 96(16): 6158-6169.

[231] Reynolds DE, Pan M, Yang J, et al. Double digital assay for single extracellular vesicle and single molecule detection. Adv Sci. 2023; 10(33):2303619.

[232] Han Y, Drobisch P, Krüger A, et al. Plasma extracellular vesicle messenger RNA profiling identifies prognostic EV signature for non-invasive risk stratification for survival prediction of patients with pancreatic ductal adenocarcinoma. J Hematol Oncol. 2023; 16(1): 7.

[233] Paras J, Maalavika P, Atchuta SD, et al. Dynamical hallmarks of cancer: phenotypic switching in melanoma and epithelial-mesenchymal plasticity. Semin Cancer Biol. 2023; 96: 48-63.

[234] Zhou Q, Wang J, Zhang Z, et al. Tracking the EMT-like phenotype switching during targeted therapy in melanoma by analyzing extracellular vesicle phenotypes. Biosens Bioelectron. 2024; 244:115819.

[235] Zhu N, Yu Y, An D, et al. Harnessing spatiotemporal-specific tumorous exosome dynamics: ultra-sensitive lanthanide luminescence detection strategy enabled by exosomal membrane engineering for melanoma immunotherapy monitoring. ACS Appl Mater Interfaces. 2024; 16(37): 49164-49175.

[236] Ye H, Wang K, Zhao J, et al. In situ sprayed nanovaccine suppressing exosomal PD-L1 by Golgi apparatus disorganization for postsurgical melanoma immunotherapy. ACS Nano. 2023; 17(11): 10637-10650.

[237] Zhang J, Guan M, Lv M, et al. Localized imaging of programmed death-ligand 1 on individual tumor-derived extracellular vesicles for prediction of immunotherapy response. ACS Nano. 2023; 17(20): 20120-20134.

[238] Huber V, Vallacchi V, Fleming V, et al. Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. J Clin Investig. 2018; 128(12): 5505-5516.

[239] Medhin L B, Beasley A B, Warburton L, et al. Extracellular vesicles as a liquid biopsy for melanoma: are we there yet? Semin Cancer Biol. 2023; 89: 92–98.

[240] Serratì S, Di Fonte R, Porcelli L, et al. Circulating extracellular vesicles are monitoring biomarkers of anti-PD1 response and enhancer of tumor progression and immunosuppression in metastatic melanoma. J Exp Clin Cancer Res. 2023; 42(1): 251.

[241] Alegre E, Zubiri L, Perez-Gracia JL, et al. Circulating melanoma exosomes as diagnostic and prognosis biomarkers. Clin Chim Acta. 2016; 454: 28-32.

[242] Guan M, Chen X, Ma Y, et al. MDA-9 and GRP78 as potential diagnostic biomarkers for early detection of melanoma metastasis. Tumor Biol. 2015; 36(4): 2973-2982.

[243] Chen X, Feng J, Chen W, et al. Small extracellular vesicles: from promoting pre-metastatic niche formation to therapeutic strategies in breast cancer. Cell Commun Signal. 2022; 20(1): 141.

[244] Porcelli L, Guida M, De Summa S, et al. uPAR⁺ extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients. J Immunother Cancer. 2021; 9(5):e002372.

[245] Goodman R, Johnson DB. Antibody-drug conjugates for melanoma and other skin malignancies. Curr Treat Options Oncol. 2022; 23(10): 1428-1442.

[246] Biteghe FAN, Chalomie NET, Mungra N, et al. Antibody-based immunotherapy: alternative approaches for the treatment of metastatic melanoma. Biomedicines. 2020; 8(9):327.

[247] Zou Y, Yang A, Chen B, et al. crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer. Drug Resist Updates. 2024; 77:101126.

[248] Tsuchikama K, Anami Y, Ha SY, et al. Exploring the next generation of antibody-drug conjugates. Nat Rev Clin Oncol. 2024; 21(3): 203-223.

[249] Dong Y, Zhang Z, Luan S, et al. Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses. J Immunother Cancer. 2024; 12(10):e009710.

[250] Yang C, Xue Y, Duan Y, et al. Extracellular vesicles and their engineering strategies, delivery systems, and biomedical applications. J Control Release. 2024; 365: 1089-1123.

[251] Xu G, Jin J, Fu Z, et al. Extracellular vesicle-based drug overview: research landscape, quality control and nonclinical evaluation strategies. Signal Transduct Target Ther. 2025; 10(1): 255.

[252] de Marchi M, Moggio EL, da Costa MCV, et al. BDE-209-exposed melanoma cells enhance metastasis and chemoresistance in C57BL/6 mice. J Hazard Mater. 2025; 497:139495.

[253] Kulkarni P, Basu R, Bonn T, et al. Growth hormone upregulates melanoma drug resistance and migration via melanoma-derived exosomes. Cancers. 2024; 16(15):2636.

[254] Németh A, Bányai GL, Dobos NK, et al. Extracellular vesicles promote migration despite BRAF inhibitor treatment in malignant melanoma cells. Cell Commun Signal. 2024; 22(1): 282.

[255] Zhang F, Zhang Z, Yang W, et al. Engineering autologous cell-derived exosomes to boost melanoma-targeted radio-immunotherapy by cascade cGAS-STING pathway activation. Small. 2025; 21(4):2408769.

[256] Gao Y, Liu J, Wu M, et al. Photosensitive hybrid γδ-T exosomes for targeted cancer photoimmunotherapy. ACS Nano. 2025; 19(4): 4251-4268.

[257] Lee Y-H, Huang C-Y. Engineered perfluorochemical cancer-derived exosomes loaded with indocyanine green and camptothecin provide targeted photochemotherapy for effective cancer treatment. Int J Nanomed. 2025; 20: 327-342.

[258] Wiklander OP, Mamand DR, Mohammad DK, et al. Antibody-displaying extracellular vesicles for targeted cancer therapy. Nat Biomed Eng. 2024; 8(11): 1453-1468.

[259] Bhatta R, Han J, Liu Y, et al. Metabolic tagging of extracellular vesicles and development of enhanced extracellular vesicle based cancer vaccines. Nat Commun. 2023; 14(1): 8047.

[260] Sabit H, Abbas S, El-Safoury MT, et al. Antibody-drug conjugates in breast cancer: navigating innovations, overcoming resistance, and shaping future therapies. Biomedicines. 2025; 13(9):2227.

[261] Cela I, Capone E, Pece A, et al. LGALS3BP antibody-drug conjugate enhances tumor-infiltrating lymphocytes and synergizes with immunotherapy to restrain neuroblastoma growth. J Transl Med. 2025; 23(1): 431.

[262] Dufrusine B, Capone E, Ponziani S, et al. Extracellular LGALS3BP: a potential disease marker and actionable target for antibody-drug conjugate therapy in glioblastoma. Mol Oncol. 2023; 17(8): 1460-1473.

[263] Wu D, Yan J, Shen X, et al. Profiling surface proteins on individual exosomes using a proximity barcoding assay. Nat Commun. 2019; 10(1): 3854.

[264] Barok M, Puhka M, Yazdi N, et al. Extracellular vesicles as modifiers of antibody-drug conjugate efficacy. J Extracell Vesicles. 2021; 10(4):e12070.

[265] Takakura Y, Takahashi Y. Strategies for persistent retention of macromolecules and nanoparticles in the blood circulation. J Control Release. 2022; 350: 486-493.

[266] Oya K, Shen LT-W, Maruo K, et al. Plasma exchange may enhance antitumor effects by removal of soluble programmed death-ligand 1 and extracellular vesicles: preliminary study. Biomedicines. 2022; 10(10):2483.

[267] Han X, Li H, Zhou D, et al. Local and targeted delivery of immune checkpoint blockade therapeutics. Acc Chem Res. 2020; 53(11): 2521-2533.

[268] Saleh NA, Rode MP, Cisilotto J, et al. MicroRNA-mediated antiproliferative effects of M1 macrophage-derived extracellular vesicles on melanoma cells. Immunol Investig. 2024; 53(1): 70-89.

[269] Deshpande RP, Wu K, Wu S-Y, et al. MHC-I upregulation by macbecin II in the solid tumors potentiates the effect of active immunotherapy. EMBO Mol Med. 2025; 17(4): 797-822.

[270] Li J, Li J, Peng Y, et al. Dendritic cell derived exosomes loaded neoantigens for personalized cancer immunotherapies. J Control Release. 2023; 353: 423-433.

[271] Lu Y, Ye H, Zhao J, et al. Small EV-based delivery of CpG ODNs for melanoma postsurgical immunotherapy. J Control Release. 2023; 363: 484-495.

[272] Wang Y, Li S, Hu M, et al. Universal STING mimic boosts antitumour immunity via preferential activation of tumour control signalling pathways. Nat Nanotechnol. 2024; 19(6): 856-866.

[273] Feng X, Liu W, Jia X, et al. Antitumor effect and immunomodulatory mechanism of “oncolytic extracellular vesicles”. Nano Lett. 2024; 24(31): 9598-9607.

[274] Mathlouthi S, Kuryk L, Prygiel M, et al. Extracellular vesicles powered cancer immunotherapy: targeted delivery of adenovirus-based cancer vaccine in humanized melanoma model. J Control Release. 2024; 376: 777-793.

[275] Zhang Y, Zuo B, Yu Z, et al. Complete remission of tumors in mice with neoantigen-painted exosomes and anti-PD-1 therapy. Mol Ther. 2023; 31(12): 3579-3593.

[276] Sancho-Albero M, Decio A, Akpinar R, et al. Melanoma extracellular vesicles membrane coated nanoparticles as targeted delivery carriers for tumor and lungs. Mater Today Bio. 2025; 30:101433.

[277] Kumar DN, Chaudhuri A, Dehari D, et al. Enhanced therapeutic efficacy against melanoma through exosomal delivery of hesperidin. Mol Pharm. 2024; 21(6): 3061-3076.

[278] Teng Y, Luo C, Qiu X, et al. Plant-nanoparticles enhance anti-PD-L1 efficacy by shaping human commensal microbiota metabolites. Nat Commun. 2025; 16(1): 1295.

[279] Van Delen M, Derdelinckx J, Wouters K, et al. A systematic review and meta-analysis of clinical trials assessing safety and efficacy of human extracellular vesicle-based therapy. J Extracell Vesicles. 2024; 13(7):e12458.

[280] You Y, Tian Y, Guo R, et al. Extracellular vesicle-mediated VEGF-A mRNA delivery rescues ischaemic injury with low immunogenicity. Eur Heart J. 2025; 46(17): 1662-1676.

[281] Zhou X, Jia Y, Mao C, et al. Small extracellular vesicles: Non-negligible vesicles in tumor progression, diagnosis, and therapy. Cancer Lett. 2024; 580:216481.

[282] Chew FY, Tsai CH, Chang KH, et al. Exosomes as promising frontier approaches in future cancer therapy. World J Gastrointest Oncol. 2025; 17(1):100713.

[283] Xiao G, Xu Z, Luo F. Combinational antitumor strategies of exosomes as drug carriers: mini review. Front Pharmacol. 2023; 13:1107329.

[284] Hyun S, Choi H, Sub Y, et al. Safety and anti-inflammatory effects of engineered extracellular vesicles (ILB-202) for NF-κB inhibition: a double-blind, randomized, placebo-controlled phase 1 trial. J Extracell Vesicles. 2025; 14(9):e70141.

[285] Guo R, Du F, Xiang X, et al. Ultrasound-enhanced Pt-coordinated polymer immunopotentiators and heterogenic fusion membrane-based multifunctional tumor vaccine nanoplatforms for melanoma treatment. Signal Transduct Target Ther. 2025; 10(1): 278.

[286] Zhang Q, Jeppesen DK, Higginbotham JN, et al. Comprehensive isolation of extracellular vesicles and nanoparticles. Nat Protoc. 2023; 18(5): 1462-1487.

[287] Thakur A, Rai D. Global requirements for manufacturing and validation of clinical grade extracellular vesicles. J Liq Biopsy. 2024; 6:100278.

[288] de Voogt WS, Frunt R, Leandro RM, et al. EV-Elute: A universal platform for the enrichment of functional surface marker-defined extracellular vesicle subpopulations. J Extracell Vesicles. 2024; 13(12):e70017.

[289] Imai S, Nagamori K, Onishi U, et al. Induction of antigen-specific regulatory T cells by engineered extracellular vesicles. Drug Deliv. 2025; 32(1):2586305.

[290] Jiang M, Jike Y, Liu K, et al. Exosome-mediated miR-144-3p promotes ferroptosis to inhibit osteosarcoma proliferation, migration, and invasion through regulating ZEB1. Mol Cancer. 2023; 22(1): 113.

[291] Angelica O. Extracellular vesicles in cancer progression. Semin Cancer Biol. 2021; 76: 139-142.

RIGHTS & PERMISSIONS

2026 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.